Gilead Sciences (GILD) Stock Rating Reiterated After HIV Drug Approval

AI Summary

Cantor Fitzgerald has reiterated its rating on Gilead Sciences (GILD) following the approval of a new HIV drug. The approval is significant as it supports Gilead's position in the HIV treatment market. Market analysts are closely watching the impact of this approval on Gilead's stock performance and overall revenue growth. Investors should consider this reaffirmed rating when evaluating their positions in GILD, given the potential for increased sales.